Lucid Diagnostics (NASDAQ: LUCD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Lucid Diagnostics reported 0 open-market sales and 1 open-market purchase of 245,000 shares ($245,000), by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 20 May 2026 | Matheis Dennis | Director | Open-market purchase | +245,000 | $1.00 | 1,033,443 | Form 4 |
| 20 February 2026 | Gordon Michael Adam | General Counsel and Secretary | Grant or award | +300,000 | — | 1,000,000 | Form 4 |
| 20 February 2026 | O'Neil Shaun | President and COO | Grant or award | +620,000 | — | 1,446,763 | Form 4 |
| 20 February 2026 | McGrath Dennis M | Chief Financial Officer | Grant or award | +470,000 | — | 1,813,569 | Form 4 |
| 20 February 2026 | Cox James L | Director | Grant or award | +123,000 | — | 405,120 | Form 4 |
| 20 February 2026 | Lapidus Stanley | Director | Grant or award, 10b5-1 plan | +123,000 | — | 337,392 | Form 4 |
| 20 February 2026 | Palumbo John R | Director | Grant or award | +123,000 | — | 338,000 | Form 4 |
| 20 February 2026 | Sokolov Jacque J | Director | Grant or award | +123,000 | — | 320,460 | Form 4 |
| 20 February 2026 | Sparks Ronald M | Director | Grant or award | +123,000 | — | 320,460 | Form 4 |
| 20 February 2026 | White Debra | Director | Grant or award | +123,000 | — | 235,800 | Form 4 |
| 20 February 2026 | Matheis Dennis | Director | Grant or award | +123,000 | — | 788,443 | Form 4 |
| 20 February 2026 | Aklog Lishan | Chief Executive Officer | Grant or award | +2,170,000 | — | 3,636,627 | Form 4 |
| 20 August 2025 | Matheis Dennis | Director | Open-market purchase | +100,000 | $1.02 | 665,443 | Form 4 |
| 22 May 2025 | Matheis Dennis | Director | Open-market purchase | +33,218 | $1.32 | 350,000 | Form 4 |
| 21 May 2025 | Matheis Dennis | Director | Open-market purchase | +129,684 | $1.32 | 316,782 | Form 4 |
| 20 May 2025 | Matheis Dennis | Director | Open-market purchase | +187,098 | $1.30 | 187,098 | Form 4 |
| 20 February 2025 | Sparks Ronald M | Director | Grant or award | +112,800 | — | 197,460 | Form 4 |
| 20 February 2025 | White Debra | Director | Grant or award | +112,800 | — | 112,800 | Form 4 |
| 20 February 2025 | Gordon Michael Adam | General Counsel and Secretary | Grant or award | +300,000 | — | 700,000 | Form 4 |
| 20 February 2025 | McGrath Dennis M | Chief Financial Officer | Grant or award | +300,000 | — | 1,343,569 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lucid Diagnostics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.